Navigation Links
Gemin X Pharmaceuticals Selects and Deploys Clinical Force CTMS
Date:4/6/2009

Clinical Force, a web based CTMS (Clinical Trial Management System), has announced that Gemin X Pharmaceuticals has selected and deployed Clinical Force to manage worldwide clinical trials. "We have deployed the Project Management, Regulatory/Ethics Management, CRF Tracking, Visit Reports, and Site Payments modules as well as the Offline Client. Future phases of our project will include integration to our EDC system(s), rollout of the new Clinical Supplies module" said Kevin Rechkemmer, Clinical Information Science Manager, Clinical Operations, Gemin X Pharmaceuticals.

Raleigh, NC (PRWEB) April 6, 2009 -- Clinical Force, the first SaaS, software as a service, CTMS, announces that Gemin X Pharmaceuticals has selected Clinical Force to manage worldwide clinical trials.

As an emerging biotech company working in oncology therapeutics with operations in Montreal Canada and Malvern Pennsylvania, Gemin X Pharmaceuticals selected Clinical Force based on its cost effective monthly subscription fees, adaptable infrastructure requiring no internal IT investment or support, and flexible user interface. In addition, Gemin X expects to improve study efficiencies by requiring their CROs to use Clinical Force on outsourced studies.

"After an extensive review process we felt Clinical Force's modular and cost effective solution met our needs. We have deployed the Project Management, Regulatory/Ethics Management, CRF Tracking, Visit Reports, and Site Payments modules as well as the Offline Client. Future phases of our project will include integration to our EDC system(s), rollout of the new Clinical Supplies module as well as other innovative functional changes to the system that will lead to process efficiencies and cost savings," said Kevin Rechkemmer, Clinical Information Science Manager, Clinical Operations, Gemin X Pharmaceuticals.

About Clinical Force
Clinical Force delivers a fully functional Clinical Trials Management System (CTMS) to Clinical Research Organizations and Sponsors. Clinical Force is the first company to deliver the CTMS in the Software as a Service (SaaS) model enabling quick installation and a cost effective solution. Organizations in North America, South America, Africa and Europe are successfully using the CTMS to improve internal efficiencies and real time visibility of all studies from an easy to use web based solution. Clinical Force is a privately held company with strong life science pedigree, the company has offices in the US and Europe. www.clinicalforce.com

About Gemin X Pharmaceuticals
Gemin X is developing first-in-class cancer therapeutics based on reinitiating programmed cell death, or apoptosis, inducing cancer cell self-digestion, or autophagy, and the inhibition of metabolism in cancerous cells. Gemin X currently has several clinical development programs underway, including Phase 2 clinical trials for its lead product candidates obatoclax (GX15-070), an innovative pan Bcl-2 inhibitor, and GMX1777, a novel inhibitor of NAD+ synthesis, and preclinical studies for its Telomere Capping and SMAC Mimetic programs. Potential treatment indications for the full scope of pipeline programs span a broad range of hematological and solid tumors, including mantle cell lymphoma (MCL), melanoma, glioblastoma, small cell lung cancer (SCLC), refractory acute lymphoblastic leukemia (ALL) and mastocytosis.

For more information, please visit www.geminx.com

###

Read the full story at http://www.prweb.com/releases/CTMS/biotechnology/prweb2292394.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

Related biology technology :

1. Idenix Pharmaceuticals to Present at the Canaccord Adams Hepatitis C Conference
2. VIA Pharmaceuticals Receives Anticipated Notice From NASDAQ
3. Savient Pharmaceuticals to Raise $31 Million Through Registered Direct Offering
4. Amylin Pharmaceuticals Provides Shareholders with Update Regarding Recent Developments
5. Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2008 Financial Results
6. NovaBay Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2008 Financial Results
7. Alseres Pharmaceuticals, Inc. Complies with NASDAQ Rule Regarding Recently Filed 10-K
8. Novavax Announces New Capital Infusion Through a Strategic Alliance with Cadila Pharmaceuticals of India
9. VIA Pharmaceuticals to Present Poster at AHA Arteriosclerosis, Thrombosis and Vascular Biology Conference 2009
10. Angiotech Pharmaceuticals, Inc. announces License Agreement with Baxter International Inc.
11. Peregrine Pharmaceuticals Awarded New U.S. Patent Further Strengthening Its Anti-Phospholipid Patent Portfolio
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2017)... SPRING, Md. and RESEARCH TRIANGLE ... United Therapeutics Corporation (NASDAQ: UTHR ) today ... of up to $250 million of the company,s common ... remain open through December 31, 2017. Purchases may be ... in privately negotiated transactions from time to time as ...
(Date:4/27/2017)... ... April 27, 2017 , ... Arrowhead Publishers is pleased to ... coming to San Diego, CA on September 27-28, 2017. Leaders from the pharmaceutical, ... advances in the treatment of various types of pain. There are also extended ...
(Date:4/27/2017)... ... April 27, 2017 , ... The ... Communication Award goes to Jayson Lusk, a consummate communicator who promotes agricultural science ... advocate for science, as he explains how innovation and growth in agriculture are ...
(Date:4/26/2017)... ... April 26, 2017 , ... Led by ... I clinical trials comes to Tampa, San Francisco and Boston in 2017. ... FDA regulated organizations such as Pfizer Inc., Teva Pharmaceuticals, Advaxis, Inc., Ocular Therapeutix ...
Breaking Biology Technology:
(Date:4/11/2017)... -- Research and Markets has announced the addition of ... offering. ... market to grow at a CAGR of 30.37% during the period ... has been prepared based on an in-depth market analysis with inputs ... growth prospects over the coming years. The report also includes a ...
(Date:4/11/2017)... NXT-ID, Inc. (NASDAQ:   NXTD ) ("NXT-ID" or ... independent Directors Mr. Robin D. Richards and Mr. ... the company,s corporate governance and expertise. ... Gino Pereira , Chief Executive Officer said," ... and benefiting from their considerable expertise as we move forward ...
(Date:4/5/2017)... SEATTLE , April 5, 2017  The Allen ... the Allen Cell Explorer: a one-of-a-kind portal and dynamic ... large-scale 3D imaging data, the first application of deep ... edited human stem cell lines and a growing suite ... the platform for these and future publicly available resources ...
Breaking Biology News(10 mins):